Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · Real-Time Price · USD
2.240
-0.170 (-7.05%)
At close: Mar 31, 2025, 4:00 PM
2.281
+0.041 (1.81%)
After-hours: Mar 31, 2025, 6:47 PM EDT
Organovo Holdings Revenue
Organovo Holdings had revenue of $24.00K in the quarter ending December 31, 2024, with 380.00% growth. This brings the company's revenue in the last twelve months to $122.00K, down -49.59% year-over-year. In the fiscal year ending March 31, 2024, Organovo Holdings had annual revenue of $109.00K, down -70.54%.
Revenue (ttm)
$122.00K
Revenue Growth
-49.59%
P/S Ratio
25.01
Revenue / Employee
$6,100
Employees
20
Market Cap
3.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ONVO News
- 4 days ago - Organovo Provides Business Update - GlobeNewsWire
- 6 days ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire
- 12 days ago - Organovo Announces Reverse Stock Split - GlobeNewsWire
- 20 days ago - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - GlobeNewsWire
- 25 days ago - Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - GlobeNewsWire
- 4 weeks ago - Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company - GlobeNewsWire
- 3 months ago - Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - GlobeNewsWire
- 4 months ago - Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - GlobeNewsWire